TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03229018

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Voxel size
Description: 200 μm and 300 μm Voxel Sizes
Study: NCT00896532

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Zoledronic acid
Description: Zoledronic acid 5 mg administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 5 mg administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 5 mg administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 5 mg administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 5 mg administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Zoledronic acid 5 mg administered intravenously
Study: NCT00594347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumo 23
Description: Vaccine (Pneumo 23)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar
Description: Vaccine (Prevnar)
Study: NCT03839303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Infra-zygomatic Mini Implant Supported Appliance
Description: 1. leveling and alignment of the four maxillary incisors~2. infra zygomatic mini-implant will be placed bilaterally~3. wire frame work that is designed resembling the inner bow of headgear will be adapted to the upper arch~4. a heavy arch wire engaging the 4 incisors will be attached to the wire frame work~5. orthopedic force will be delivered from the mini-implants to the wire frame work

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high pull head gear
Description: 1. acrylic maxillary splint is made with flying tubes~2. high pull head gear is adapted to be inserted in the flying tubes
Study: NCT02656225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niferex
Description: one tablet,once daily, orally after breakfast Duration:4 weeks
Study: NCT01020734

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Study: NCT02462642

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brahmi
Description: Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brahmi
Description: Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
Study: NCT01020734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Study: NCT01176916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromasin (exemestane)
Description: the dosage, frequency and duration base on the LPD approved by SFDA.
Study: NCT04515966

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Injection [Solu-Medrol]
Description: A total 1 ml of injectate consisting of 0.5 ml of depo-Medrol (methylprednisolone acetate 40mg/ml) and 0.5 mL of 1% lidocaine will be injected into the carpal tunnel under ultrasound guidance to deliver it into the target area. After completion of the injection, the distal carpal tunnel is scanned to ensure injectate distribution within the distal aspect of the carpal tunnel.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wrist splint
Description: A standard wrist splint
Study: NCT00759070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + emtricitabine + efavirenz
Description: Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)~+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily
Study: NCT01020734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study: NCT02462642

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules - Dry starch filled in identical hard gelatin capsules
Study: NCT05829785

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy monitor
Description: tissue oxygen saturation monitoring combined with vascular occlusion test

Intervention type: DEVICE
Intervention: Near-infrared spectroscopy monitor
Description: tissue oxygen saturation monitoring combined with vascular occlusion test
Study: NCT02013258

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal oxytocin
Description: This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
Study: NCT00759070

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + emtricitabine + lopinavir/ritonavir
Description: Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
Study: NCT02500186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luseogliflozin
Description: Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luseogliflozin
Description: Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
Study: NCT01020734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study: NCT02013258

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.
Study: NCT02561767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bone marrow-derived mesenchymal stem cells
Description: BM-MSCs is harvested from third-party health volunteer donors.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline as placebo of MSCs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Induction therapy (ATG or Basiliximab)
Description: ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction therapy (ATG or Basiliximab)
Description: ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maintenance therapy (Low-dose CNI + MPA + steroids)
Description: Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
Study: NCT01789177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometry
Description: Patients will be provided with plastic, disposable incentive spirometers postoperatively

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postoperative chest physiotherapy
Description: Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
Study: NCT02561767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maintenance therapy (Low-dose CNI + MPA + steroids)
Description: Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
Study: NCT02366364

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral administration of placebo consumption on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 375 mg
Description: Single oral administration of 375 mg consumption on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 500 mg
Description: Single oral administration of 500 mg consumption on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRX-1074 750 mg
Description: Single oral administration of 750 mg consumption on Day 1
Study: NCT02745145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abituzumab 1500 mg
Description: Participants received Abituzumab 1500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abituzumab 500 mg
Description: Participants received Abituzumab 500 mg administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants received Placebo matched to Abituzumab administered as an intravenous infusion for 1 hour every 4 weeks up to Week 64.
Study: NCT00710125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPX-150 for Injection
Description: Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
Study: NCT01757158

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cs-131 brachytherapy seeds
Description: Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
Study: NCT00561626

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high fat diet followed by low fat diet
Description: High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: low fat diet followed by high fat diet
Description: Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
Study: NCT02844062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-EGFRvIII CAR T cells
Description: CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 250 mg/m\^2 d1-3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/m\^2 d1-3
Study: NCT02338232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study: NCT00186953

Intervention type: DRUG
Group type: OTHER
Intervention: Optison
Description: Intervention description:~Based on recommendation by the FDA, we began with a dose of 0.125ml/m\^2 and escalated at 0.15 ml/m\^2 increments, to 0.275 ml/m\^2 and 0.425ml/m\^2 and 0.500ml/m\^2. We will now continue to escalate the dose of Optison at 0.300ml/m\^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer.
Study: NCT03826368

Intervention type: DIETARY_SUPPLEMENT
Intervention: Hemp-derived botanical dietary supplement
Description: Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.

Intervention type: DIETARY_SUPPLEMENT
Intervention: Hemp-derived botanical dietary supplement
Description: Subjects currently taking phytocannabinoid Hemp-derived botanical dietary supplements during recovery from brain injury.
Study: NCT01832584

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RGC

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RGC

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02500186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luseogliflozin
Description: Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal containing different carbohydrate ratio and GI value
Description: High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal containing different carbohydrate ratio and GI value
Description: High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal containing different carbohydrate ratio and GI value
Description: High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate
Study: NCT03092050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Imagery and Mindfulness
Description: This is a behavioral intervention using guided imagery and mindfulness techniques.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitated Discussion
Description: This is a behavioral intervention that involves discussion and group support.
Study: NCT03308188

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-health program
Description: The Goalistics Chronic Pain Management Program, referred to as the E-health program in EMPOWER, was developed from cognitive, behavioral, interpersonal, and self-management interventions with demonstrated efficacy in traditional face-to-face or group settings. It is patient-centered, having been developed based on substantial input from people with chronic pain and chronic pain professionals.
Study: NCT03778086

Intervention type: PROCEDURE
Intervention: gonioscopy
Description: gonioscopic observation and grading of iridocorneal angle

Intervention type: PROCEDURE
Intervention: gonioscopy
Description: gonioscopic observation and grading of iridocorneal angle
Study: NCT03686969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octanorm
Description: Octanorm 0.5g/kg/week

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01044563

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breathing training
Description: Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
Study: NCT03371888

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma intramuscular injections
Description: A platelet-rich plasma intramuscular injections into the trigger points of painful muscles were performed.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: 0,9% NaCl intramuscular injections
Description: A 0,9% NaCl intramuscular injections into the trigger points of painful muscles were performed.
Study: NCT01789177

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative chest physiotherapy
Description: Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
Study: NCT01651000

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CTAP101 30 μg capsules
Description: CTAP101 30 μg capsule taken daily at bedtime.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sugar pill to CTAP101 30 μg capsules
Description: Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill to CTAP101 30 μg capsules
Description: Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
Study: NCT01044563

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress management
Description: Cognitive reconstructive strategies for stress management
Study: NCT00560755

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ProQuad®
Description: ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.
Study: NCT00769119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg, oral tablet, twice daily for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x Matched placebo, oral tablet, twice daily for 28 days
Study: NCT03696680

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FSRT Stereotactic radiation therapy
Description: For each metastasis, dose of 30 Gy in 3 fractions at 10 Gy / fraction over 7 days
Study: NCT02024178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Study: NCT02147873

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: birinapant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Azacitidine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Study: NCT04663490

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil to Lymphocyte Ratio
Description: Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count

Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil to Lymphocyte Ratio
Description: Zahorec et al. identified the neutrophil-lymphocyte ratio (NLR) as an inflammation marker in critical patients, defining as the absolute neutrophil count divided by the absolute lymphocyte count
Study: NCT06770166

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiological serum mouthwash
Description: Physiological serum contains sodium chloride : 0.009 g/ml, sodium 154 (mEq/I), chloride 154 (mEq/I)\].

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: Chlorhexidine mouthwash contains 0.12% chlorhexidine digluconate and 0.15% benzydamine hydrochloride.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chamomile mouthwash
Description: Chamomile mouthwash contains 10% chamomile in physiological serum.
Study: NCT03232333

Intervention type: DEVICE
Intervention: Biologic wound graft
Description: Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
Study: NCT01488513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sphingosine kinase-2 inhibitor ABC294640
Description: Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
Study: NCT02721953

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Butyrate
Description: Butyrate

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01395290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 20.000 IU per week, oral
Study: NCT02147873

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04485585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9006-1
Description: * Administration to the T/T+M group: 0.2 mg of BR9006-1 will be administered one capsule once a day, five-day repeated-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR9006-2
Description: * Administration to the M group: 50 mg of BR9006-2 will be administered one tablet once a day, eleven-day repeated-dose~* Administration to the T+M group: 50 mg of BR9006-2 will be administered one tablet once a day, five-day repeated-dose
Study: NCT01425099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a commonly used corticosteroid used for a variety of medical condiitons

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
Study: NCT03607773

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Behavioural Intervention (MBI) group
Description: While every MBI session is different, in general they will help you develop skills in focused attention, and emotional and behavioural regulation in a group environment made up of other people with MS who may share common experiences with you. MBI sessions are group-based which means you will be attending the sessions with other people who are also in this study and facilitated by trained personnel .
Study: NCT03163420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium
Description: Diclofenac potassium 50 mg granules for oral solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fructose
Study: NCT00927563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone
Description: pill, 100-300mg/day for 8 weeks
Study: NCT00578643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Days -9 through -6~1 mg/kg initially (based on weight)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Day -5 through Day -2~Dose is based on weight:~Less than 15 kg: 3 mg~More than 15 kg to 30 kg: 5 mg~More than 30 kg: 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Days -5 through -2~50 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Day -5 through Day -2~30 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Infusion
Description: Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10\^8/kg recipient weight; for cord blood ≥ 3 X 10\^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10\^/kg CD34+ cells.